Unknown

Dataset Information

0

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.

ABSTRACT:

SUBMITTER: Tashkin DP 

PROVIDER: S-EPMC5014629 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.

Tashkin Donald P DP   Roth Michael D MD   Clements Philip J PJ   Furst Daniel E DE   Khanna Dinesh D   Kleerup Eric C EC   Goldin Jonathan J   Arriola Edgar E   Volkmann Elizabeth R ER   Kafaja Suzanne S   Silver Richard R   Steen Virginia V   Strange Charlie C   Wise Robert R   Wigley Fredrick F   Mayes Maureen M   Riley David J DJ   Hussain Sabiha S   Assassi Shervin S   Hsu Vivien M VM   Patel Bela B   Phillips Kristine K   Martinez Fernando F   Golden Jeffrey J   Connolly M Kari MK   Varga John J   Dematte Jane J   Hinchcliff Monique E ME   Fischer Aryeh A   Swigris Jeffrey J   Meehan Richard R   Theodore Arthur A   Simms Robert R   Volkov Suncica S   Schraufnagel Dean E DE   Scholand Mary Beth MB   Frech Tracy T   Molitor Jerry A JA   Highland Kristin K   Read Charles A CA   Fritzler Marvin J MJ   Kim Grace Hyun J GHJ   Tseng Chi-Hong CH   Elashoff Robert M RM  

The Lancet. Respiratory medicine 20160725 9

<h4>Background</h4>12 months of oral cyclophosphamide has been shown to alter the progression of scleroderma-related interstitial lung disease when compared with placebo. However, toxicity was a concern and without continued treatment the efficacy disappeared by 24 months. We hypothesised that a 2 year course of mycophenolate mofetil would be safer, better tolerated, and produce longer lasting improvements than cyclophosphamide.<h4>Methods</h4>This randomised, double-blind, parallel group trial  ...[more]

Similar Datasets

Unknown Mycophenolate mofetil for methotrexate-resistant juvenile localized scleroderma.
| S-EPMC7937018 | biostudies-literature
Unknown Combining Pirfenidone With Mycophenolate Mofetil for Systemic Sclerosis-Related Interstitial Lung Disease (Scleroderma Lung Study III): An Investigator-Initiated, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.
| S-EPMC12648624 | biostudies-literature
Unknown Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.
| S-EPMC2678035 | biostudies-literature
Unknown Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II.
| S-EPMC5560126 | biostudies-literature
Unknown Efficacy and Safety of Pharmacokinetically-Driven Dosing of Mycophenolate Mofetil for the Treatment of Pediatric Proliferative Lupus Nephritis-A Double-Blind Placebo Controlled Clinical Trial (The Pediatric Lupus Nephritis Mycophenolate Mofetil Study).
| S-EPMC11258879 | biostudies-literature
Unknown Using Transitional Changes on High-Resolution Computed Tomography to Monitor the Impact of Cyclophosphamide or Mycophenolate Mofetil on Systemic Sclerosis-Related Interstitial Lung Disease.
| S-EPMC6994370 | biostudies-literature
Unknown Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease.
| S-EPMC2176114 | biostudies-literature
Unknown Long-Term Treatment With Azathioprine and Mycophenolate Mofetil for Myositis-Related Interstitial Lung Disease.
| S-EPMC6945652 | biostudies-literature
Unknown Effect of tacrolimus with mycophenolate mofetil or cyclophosphamide on the renal response in systemic lupus erythematosus patients.
| S-EPMC11654433 | biostudies-literature
Transcriptomics Systemic sclerosis skin disease trajectory during mycophenolate mofetil treatment
2017-01-01 | GSE76885 | GEO